Biotech drugs are very expensive, costing $50,000 or more per patient per year. This could become a $1.5+ Trillion spending problem in the U.S. by 2025.
A significant majority of these drugs, however, provide excellent therapeutic response in 5-20% of treated patients.
The way we price, treat, and pay for biotech drugs must be redefined – the solutions that make sense and provide clarity to all stakeholders.
We have built a transformative platform to practice a patient-centric, precision medicine protocol with an objective of providing therapeutic, cost, and time advantages to payers and patients.
Equally, this platform provides significant advantages to pharma and biotech companies.